Author | Daniel Catenacci, MD | OncLive

Author | Daniel Catenacci, MD

Articles

Dr. Catenacci on the Challenges of Developing Novel Therapies in Gastroesophageal Cancer

July 02, 2020

Video

Daniel Catenacci, MD, discusses the challenges of developing novel therapies in gastroesophageal adenocarcinoma.

Dr. Catenacci on Treatment Selection in Esophagogastric Junction Adenocarcinoma

December 07, 2019

Video

Daniel Catenacci, MD, discusses factors that may guide treatment selection for patients with esophagogastric junction adenocarcinoma.

Dr. Catenacci on Study of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer

March 01, 2018

Video

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, University of Chicago Medicine, discusses a study of margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) in gastroesophageal junction (GEJ) or gastric adenocarcinoma.

Dr. Catenacci on Results of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer

January 20, 2018

Video

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, Univeristy of Chicago Medicine, discusses margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) as treatment for patients with advanced HER2-positive gastroesophageal junction (GEJ) or gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

x